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Background: Multiple sclerosis (MS) is commonly associated with psychological
complications. Previous research by Hayter and colleagues (2016) found that in patients with
MS, health anxiety (HA) can account for part of the variance in quality of life (QoL) independent
of physical and cognitive impairment caused by the disease. MS patients with HA perceived
their intact physical and cognitive performance as impaired relative to those without HA and
attributed the impairment to MS. These misperceptions might be useful targets in the treatment
of HA in MS using cognitive behaviour therapy (CBT). Aims: Study 1 sought to replicate
the main findings from Hayter et al. (2016). Study 2 examined the impact of HA-focused
CBT in a case series. Method: In Study 1, twenty participants with MS were screened for
HA and assigned to either a high or low HA group. They completed assessments of cognitive
and physical functioning before rating their performance on these tasks, followed by measures
of QoL, mood and physical disability. Four participants in the high HA group subsequently
received six sessions of CBT using a consecutive AB case series in Study 2. Results: Study
1 replicated the main findings from the earlier study. In Study 2, three of the four patients
who received treatment showed substantial improvements in HA and mood and all showed
improvement in QoL. Conclusion: Given the high rates of HA in MS patients and its impact
on QoL, this case series suggests that a brief CBT intervention could significantly improve
patients’ wellbeing.
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Introduction
Multiple sclerosis (MS) is the most common progressive neurological condition affecting
adults of working age, with a prevalence rate of 0.1% in the UK population. Relapsing and
remitting multiple sclerosis (RRMS) is the most common form of MS, affecting around 80%
of patients (Compston and Coles, 2008). Following an initial attack that can impact both
physical (e.g. fatigue, numbness, pain, blurred vision) and cognitive functioning (e.g. slowed
processing speed, attentional problems) through demyelination of brain nerve fibres, patients
can recover functioning for an unpredictable period before further attacks cause progressive
deterioration. Given the unpredictable and fluctuating nature of RRMS, it is unsurprising
that many patients worry about when further attacks may occur, with rates of anxiety, in
particular health anxiety (HA), high in this patient group (Chwastiak et al., 2002; Kehler and
Hadjistavropoulos, 2009; Korostil and Feinstein, 2007). Although earlier work has focused on
general anxiety and depression, more recent work suggests that HA may be particularly relevant
to the problems experienced by MS patients. Previous research found that RRMS patients
with HA had lower quality of life (QoL) compared with patients without HA independent
of physical disability (Hayter et al., 2016). They also found that the health anxious RRMS
patients misappraised their performance on physical and cognitive tasks and suggested that
these might be targets for treatment using cognitive behavioural therapy (CBT) to reduce HA,
and potentially improve QoL. The studies presented here first sought to replicate the main
findings from the earlier study but then went on to treat the health anxious RRMS patients
using a brief CBT intervention; presenting the findings from a consecutive AB treatment case
series.
Several studies have found that emotional factors are more predictive of a patient’s
subjectively rated QoL than physical or cognitive impairment (Benedict et al., 2005; Dennison
et al., 2009; Janssens et al., 2003). For example, Benedict et al. (2005) found that cognitive
dysfunction accounted for none of the variance in a measure of health-related QoL but instead
was predicted by both depression and fatigue. Janssens et al. (2003) found in their study that
the extent to which physical disability affects QoL in MS patients was moderated by anxiety
and depression.
Cognitive accounts of anxiety and depression state that a person’s symptoms are maintained
through processes linked to unduly negative appraisals. Of particular relevance here is the
cognitive model of HA (Salkovskis and Warwick, 1986; Warwick and Salkovskis, 1990).
When a person experiences ambiguous physical or cognitive symptoms (often due to ‘normal’
bodily variations), their prior beliefs about illness lead to misinterpretation of these symptoms
as signs of severe threat (i.e. a severe illness). In the model, the person remains focused on threat
relevant information through attentional, physiological and behavioural processes that lead to
further misinterpretation and potential increases in anxiety. The model has recently begun to
be applied to patients in physical health settings [e.g. the CHAMP trial (Tyrer et al., 2011b)].
As such, it is particularly relevant to RRMS as high levels of anxiety can lead to transient
physiological symptoms that mirror those of the illness (e.g. pins and needles, dizziness, pains,
etc.). Hence RRMS patients vulnerable to HA may experience these normal bodily variations
but misappraise them as signs of MS relapse, leading to increased anxiety and thus further
anxiety symptoms. This would suggest that the rates of HA in RRMS are likely to be high and
indeed Kehler and Hadjistavropoulos (2009) found the rate to be approximately 25%, while
Hayter et al. (2016) found 29%.
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Misappraisal in terms of exaggerated threat has been found in studies with MS patients
who focus excessively on bodily sensations (Vercoulen et al., 1996) and attribute them to
MS (Skerrett and Moss-Morris, 2006) with associated increases in fatigue and poor social
adjustment. Catastrophizing about bodily sensations has also been found to predict reduced
psychological functioning even after MS-related factors have been controlled for (Osborne
et al., 2007). MS patients who are anxious or depressed are also more likely than those not
anxious or depressed to misperceive themselves as more cognitively impaired than they actually
are based on objective neuropsychological test performance (Benedict et al., 2004; Julian et al.,
2007; Lovera et al., 2006; Maor et al., 2001; Middleton et al., 2006).
In a recent study, Hayter et al. (2016) found that health anxious patients also had lower QoL
compared with non-health anxious RRMS patients even after their level of physical disability
was controlled for. The health anxious patients were also more likely than non-health anxious
patients and healthy controls to attribute their ambiguous bodily sensations to their MS. Hayter
et al. asked their participants to complete short ‘objective’ assessments of their cognitive and
physical functioning as well as rate their perceived performance on these tasks. Even though
there was no difference in performance, the health anxious MS patients subjectively rated their
performance as worse than the non-health anxious and control groups and were more likely to
attribute their poor performance to their MS. These findings suggest that HA in patients with
RRMS is leading them to perceive themselves as more physically and cognitively impaired
than they really are: with a concomitant reduction in QoL.
The implication of the above finding is that potentially QoL in health anxious RRMS patients
could be improved through treatment focused on HA. Randomized controlled trials (RCTs)
have shown CBT to be effective in treating HA in psychiatric populations (Clark et al., 1998;
Greeven et al., 2007; Seivewright et al., 2008). The approach is to help patients actively explore
(through discussion and behavioural experiments) the validity of an alternative understanding
of their problem as one of misinterpretation of bodily sensations that lead to safety seeking
behaviours, hypervigilance, physiological arousal etc., that in turn maintain their symptoms –
rather than one of having a serious illness. More recently the approach has been applied in a
physical health setting in the CHAMP trial (Tyrer et al., 2013). This was a multi-centre RCT
where patients with HA across a range of co-morbid physical health conditions received on
average six sessions of a manualized CBT intervention for HA delivered by non-CBT specialist
health care professionals in secondary care settings. Twice as many patients in the CBT group
achieved normal levels of HA compared with those in the control group with no significant
increase in total treatment cost. This led the authors to suggest that a brief CBT intervention
was cost effective in treating HA in patients with physical health conditions.
Relatively few studies have explored the effectiveness of CBT in treating co-morbid
psychological problems in MS patients. A Cochrane review of psychological interventions in
MS (Thomas et al., 2006) found that generic CBT led to significant improvements in depression
symptoms in two studies that compared it with treatment as usual (Larcombe and Wilson, 1984;
Mohr et al., 2000) but found no difference when compared with anti-depressant medication
(Mohr et al., 2001). Askey-Jones et al. (2013) state that to date, no studies have considered the
effectiveness of CBT in treating anxiety disorders in MS.
The misperception by MS patients of physical and cognitive functioning found in the Hayter
et al. (2016) study suggest that this could be a useful target in treatment. For example, Tang
and Harvey (2006) targeted misappraisals in a subgroup of insomnia patients whereby they
perceived themselves as having sleep problems when in fact they displayed normal patterns of
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sleep. The authors developed a behavioural experiment where patients compared their self-rated
sleep pattern against objective feedback from actigraphy, leading to improvements in patients’
subsequent sleep ratings. Similarly, using objective data from their performance on physical
and cognitive tasks might help MS patients with HA reappraise their level of functioning
and reduce levels of HA. Hence a brief adapted CBT intervention for HA (CBT-HA) may be
beneficial to patients with RRMS suffering from HA.
In the studies described here, we first attempt to replicate the main findings from the Hayter
et al. (2016) study in a different sample. Replicating these findings would provide clinical
justification for treating participants using a cognitive model of HA with a specific focus on
misappraisals of cognitive and physical functioning and allow the identification of targets for
treatment (via behavioural experiments) during therapy. Hence this study is not a full replication
of Hayter et al. Thus we hypothesized in Study 1 that RRMS patients with HA would rate their
QoL and performance on physical and cognitive tasks as lower than RRMS patients without
HA, and attribute to a greater extent their performance on these tasks to MS. In Study 2 we
present case studies of the treatment of four health anxious participants recruited from Study
1 who went on to receive a brief formulation-driven CBT-HA intervention. We expected that
the participants in Study 2 would not only show reductions in HA but also improvements in
QoL following the intervention.
Method
Design
Study 1 sought to replicate the Hayter et al. (2016) study using an independent groups design
with level of HA, high health anxiety (HiHA) or low health anxiety (LowHA), as a between-
subject factor. Participants from Study 1 with a score of 18 or above on the Short Health Anxiety
Inventory (SHAI) were invited to take part in Study 2 where they were offered six sessions of
CBT-HA in a multiple baseline across subjects case series A–B design (Barlow and Hersen,
1984) with follow-up. For this design, all patients were assigned to no-treatment baselines of
2 weeks. Individual baselines acted as control periods. CBT-HA was delivered by the study’s
lead author (N.C.) who has received doctoral level training in clinical psychology and accredited
Level 2 training in CBT (British Association for Behavioural and Cognitive Psychotherapies;
BABCP). One of the study authors (P.M.S.) was responsible for developing the cognitive model
of HA and is a recognized authority in the field. During the delivery of treatment, N.C. was
supervised by P.M.S. through fortnightly sessions using audio-recordings from treatment to
ensure adherence to the cognitive model of treatment. Follow-up of patients was planned for
5 months after completion of treatment.
Participants
Participants were recruited from the caseloads of the Community Neuro and Stroke Service and
MS Neurology nurse specialists in Bath, UK. Participants on these caseloads were identified
if they had a definitive diagnosis of RRMS within the last 10 years and were currently within
the remitting phase of their illness. Further inclusion criteria included whether the participants
were between 18 and 65 years old, were fluent in English to complete the assessment measures,
and were able to give informed consent. Potential participants were approached either by the
first author directly or by the MS nurse specialist. Problems with recruitment (recent changes in
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treatment pathways meant that very few patients at this stage in their illness were being referred
to the service) meant that only 20 eligible participants were identified and approached, with
four declining to take part. Given the low numbers, participants were also recruited from a local
MS National Therapy Centre. Many people at this stage of their illness are high functioning,
so very few with RRMS register with this organization. All seven of those with RRMS were
approached by first author but three did not respond to the initial contact. In total, 20 participants
took part in the first phase of the study, 17 females and three males (two of whom were in the
low HA group). All participants were over the age of 18 years (range 21–54 years), were white
Caucasian, and gave written informed consent to take part in the study.
Six participants who scored above 18 on the Short Health Anxiety Inventory (SHAI) were
invited to take part in Study 2. However, two declined, leaving four women with age ranges
from 22 to 43 years to take part. The details of cases and their treatment are given below in
Study 2.
Measures
Health anxiety. HA in participants was assessed with a modified version of the 14-item
Short Health Anxiety Inventory (SHAI). The 14 items assess basic HA symptoms. Scores
on the measure can range between 0 and 42. Scores above 18 indicate clinical levels of HA
(Seivewright et al., 2004) and would meet DSM diagnostic criteria for hypochondriasis (APA,
2013; Salkovskis et al., 2002) while scores above 15 suggest that the person is suffering
symptoms of HA. The SHAI is a reliable (Cronbach’s α = .89) and valid measure in the general
population (Salkovskis et al., 2002) and has been modified for use with patients with MS by
Kehler and Hadjistavropoulos (2009) (the version used in the present study). This modified
version added the statement ‘other than MS’ to items 5, 9, 11 and 12 so that participants’
responses were not limited by already having a serious health condition. Continuous monitoring
of HA in participants undergoing treatment in the second phase of this study was assessed using
a modified version of the 6-item Health Anxiety Inventory, the Very Short Health Anxiety
Inventory (VSHAI). While there is currently no published data as to the VSHAI’s reliability
and validity, it correlates highly (r = .8) with the SHAI in clinical populations (P.M. Salkovskis,
personal communication) and was used to continuously monitor symptoms during treatment
as it is very quick to complete and thus reduces the time spent in session completing measures.
Reduction in symptoms was confirmed by administering the SHAI at the end of treatment.
Mood. Although not a primary measure in the study, mood was assessed using the Patient
Health Questionnaire (PHQ-9) (Kroenke et al., 2001), a 9-item self-report measure assessing
symptoms of depression. Scores range from 0 to 27, with scores above 10 indicating some
level of depression being present. The measure has been shown to be a reliable (α = .89) and
valid measure of depression severity and is used routinely in NHS primary care settings. It has
also been shown to have good reliability and validity when assessed against other measures of
depression in MS patients (Amtmann et al., 2014).
Disability. The level of disability in participants due to MS was assessed using the Guy’s
Neurological Disability Scale (GNDS; Sharrack and Hughes, 1999). It is a MS-related disability
measure that correlates highly with objective measures of MS disability and has excellent
psychometric properties (Sharrack and Hughes, 1999). It assesses 12 domains of disability
assoociated with MS and can be administered by non-neurologists. The domains are scored out
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of 5 and it thus has a range of scores from 0 to 60, with higher scores indicating greater disability.
The measure has good internal reliability (α = .79) and correlates with other measures of
clinician-administered MS symptom measures (ibid).
Quality of life. Quality of life was measured using the Quality of Life Index (QLI; Ferrans
and Powers, 2007). This measures quality of life in terms of how satisfied the participant is with
different areas of their life, and also how important the participant rates each of these areas.
The QLI has been used in studies of various physical health conditions (including a version
tailored to MS, which was used here) demonstrating good levels of reliability (α = .79) and
validity (Stuifbergen, 1995). Scores on the measure range from 0 to 30, with higher scores
indicating higher perceived quality of life.
Cognition. The two measures of cognitive functioning used in the Hayter et al. (2016) study
were also used here. These were the Brixton Spatial Anticipation Test (BSAT; Burgess and
Shallice, 1997) and the Symbol Digit Modality Test (SDMT; Smith, 1982). Both are widely
used, valid and reliable tests with the BSAT measuring executive functioning and the SDMT
measuring processing speed and episodic memory. These tests are commonly used in the MS
research literature (e.g. Summers et al., 2008) to assess cognitive functioning.
Physical functioning. A hand grip dynamometer was used to measure physical grip strength
following a similar protocol to the Hayter et al. (2016) study and developed by Rode et al.
(2001) in a study of chronic pain. Participants were asked to grip the dynamometer as hard as
they could and a measure of their grip strength was taken. This was done three times and the
mean of these three measures was calculated.
Misperception and misattribution. Misperception of performance on the cognitive and
physical tasks was assessed using a similar measure to the one developed in the Hayter et al.
study. Following the physical and cognitive tasks, participants were asked to evaluate how well
they felt they performed compared with other people with MS on a scale from –50 (‘extremely
badly in comparison to others’) to +50 (‘extremely well in comparison to others’). They then
completed a measure of how much better they felt their performance on the tasks would have
been if they did not have MS, from 0 (‘no better’) to 100 (‘very much better’).
Procedure
In Study 1, participants initially completed the assessment of physical and cognitive functioning
before completing subjective ratings of their performance. Following this, participants
completed the GNDS, QLI, PHQ-9 and SHAI. The sessions took approximately 1 hour. The
assessment was conducted by the first author (N.C.) and took place in the participant’s home.
Participants scoring below 18 on the SHAI then received feedback on their scores
immediately following testing. Those scoring above 18 were offered the opportunity to take
part in Study 2. If participants declined treatment or were not eligible then their scores on the
measures were fed back to them in session and alternative treatment options discussed. This
was the standard care offered by the Community Neuro Rehab and Stroke Service (none of the
five participants from the MS National Therapy Centre was eligible to take part in Study 2).
Participants who agreed to take part in Study 2 were given a second set of baseline measures
(SHAI and PHQ-9) to complete 1 week later and bring to their initial treatment session 2
weeks after the assessment session. Following the individual baseline period, CBT-HA was
delivered over six weekly 60-min treatment sessions delivered in the participant’s home. The
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treatment was formulation- rather than protocol-driven but did include behavioural experiments
based on the data provided by them in the first phase of the study whereby they compared
their perceived performance on the cognitive and physical tasks with data from their actual
performance (idiosyncratic elements of treatment are presented in the case descriptions below).
As these data were already available from Study 1, it involved exploration of these data with
the participants, rather than further behavioural experimentation by them. All participants in
Study 2 received psycho-education about the symptoms of anxiety and the extent to which
they can mimic some of the symptoms of RRMS. In line with standard CBT for HA, each
case was asked to consider exploring the validity of Theory A (they are experiencing an
RRMS relapse) vs Theory B (they are misinterpreting ambiguous bodily sensations that lead to
safety seeking behaviour, hypervigilance etc. that is maintaining their symptoms) and develop
individualized behavioural experiments based on their idiosyncratic formulation. One of the
cases (Patient 2) expressed a preference for a mindfulness-based approach and so this was
used to help differentiate the content from the process of her worries about the illness. There
is some evidence of mindfulness-based approaches being used to successfully treat HA (e.g.
McManus et al., 2012) although not in patients with MS. At each treatment session participants
completed the PHQ-9 measure of mood and the VSHAI measure of HA. At the end of treatment
participants completed the SHAI, QLI and PHQ-9 before being offered a follow-up session in
5 months’ time.
Statistical analysis
Where parametric assumptions were met, parametric analysis was conducted with Bonferroni
corrections where appropriate to control Type I error when multiple comparisons were made.
For instances where parametric test assumptions are not met, Wilcox (2012) recommends
using modern robust alternative tests that are not susceptible to violations of assumptions (see
also Erceg-Hurn and Mirosevich, 2008). These include the Yuen-Welch t-test (Ty) which uses
trimmed means and Winsorized variances that are approximated to a Student’s t-distribution.
Monte Carlo simulation studies have found that the test controls Type I error while still
maintaining power when parametric assumptions have been violated (e.g. Keselman et al.,
2004). The robust alternative tests were conducted with the statistical software package R
using Wilcox’s Robust Statistic (WRS) package.
For Study 2, visual inspection of the data was used to assess the change in measures from
baseline and through treatment in terms of trend (direction of the data path) and level (relative
value or magnitude of the data) (Lane and Gast, 2013). Reliable and significant change index
(RC) in scores was calculated using the method developed by Jacobson and Truax (1991)
whereby the difference between the pre- and post-treatment scores on the measures are divided
by the standard error of the difference between the two test scores (see Appendix). To calculate
this index, the pre-treatment standard deviations of the measures from the HiHA participants
in the first phase of the study were used as representative of MS patients suffering HA.
Results
Study 1
A median-split of SHAI scores (14.50) was used to assign participants to either HiHA or
LowHA groups. Table 1 shows mean scores for demographic, mood and QLI measures across
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Table 1. Means (SD) of demographic, mood and quality of life measures across groups
LowHA HiHA
(n = 10) (n = 10)
Age 42.30 (7.27) 36.80 (7.30)
Education (no. of years) 13.20 (2.39) 13.20 (2.10)
PHQ-9 7.40 (5.58) 12.80 (7.08)
GNDS 14.20 (3.08) 13.70 (5.83)
QLI 21.52 (3.63) 15.25 (2.98)∗
QLI – adjusted for GNDS (SE) 21.56 (1.05) 15.20 (1.05)∗
LowHA, low health anxiety; HiHA, high health anxiety; PHQ-9, Patient Health Questionnaire; GNDS,
Guy’s Disability Scale; QLI, Quality of Life Index. ∗p <.05, mean difference between LowHA and HiHA.





HiHA 55.20 (13.96) 13.10 (6.01) 23.93 (13.11)
LowHA 52.10 (11.49) 13.20 (3.08) 26.38 (13.89)
HiHA, high health anxiety; LowHA, low health anxiety; SDMT, Symbol Digit Modality Test; Brixton,
Brixton Spatial Anticipation Test.
Table 3. Participants’ subjective ratings [mean (SD)] of their performance on the cognitive and physical
tasks and how much better their performance would have been without MS
HiHA LowHA
Perceived performance on handgrip task (–50 to +50) 4.00 (20.11) 14.00 (20.66)
Perceived performance on cognitive tasks (–50 to +50) –5.00 (12.69) 13.00 (16.36)∗
Performance improvement if no MS (0 to 100) 34.30 (32.05) 24.00 (20.11)
LowHA, low health anxiety; HiHA, high health anxiety. ∗p <.05.
groups. There was no difference between groups in terms of age [t (18) = 1.69, p = .12];
educational level [Ty (13.94) = 0.10, p = .99]; physical disability (GNDS) [t (18) = 0.24,
p = .82]; or mood (PHQ9) [t (18) = 1.88, p = .07]. There was a significant difference between
groups on QLI scores [t (18) = 4.23, p < .001; Bonferroni p < .05]. This effect remained
significant even when level of physical disability (GNDS) was controlled using ANCOVA
[F (1, 17) = 18.51, p < .001]. The mean (SE) scores for QLI adjusted for GNDS are also
presented in Table 1. The effect size of the difference measured by Cohen’s d was 1.89 (95%
CI 0.77, 2.85), suggesting a large significant effect.
Participants’ scores on the assessment of cognitive and physical abilities are presented in
Table 2. As predicted, there was little difference between groups on any of these measures (all
F values <1).
Table 3 summarizes the data from participants’ subjective ratings of their performance on
the physical and cognitive tasks as well as the extent to which they attributed their performance
to MS. The mean scores show that LowHA participants rated their performance in comparison
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with others with MS as higher than those in the HiHA group on the tasks and attributed less
of their performance to MS. A MANOVA with group as a between-subjects factor and ratings
of performance on the physical and cognitive tasks as dependent variables, showed an overall
effect of group [F (2,17) = 4.86, p = .02]. Subsequent univariate tests showed a significant
difference in ratings of cognitive performance [F (1,18) = 7.55, p = .01] but no significant
difference in ratings of physical performance [F (1,18) = 1.20, p = .29]. The effect size of
the difference between groups on ratings of cognitive task performance was d = 1.23 (95% CI
0.23, 2.13), suggesting a large effect of group on this measure. An independent groups t-test
revealed no significant difference between groups on how much better they thought they would
have performed if they did not have MS [t (18) = 0.86, p = .40].
Study 2
Case descriptions
See the ‘Procedure’ section for common elements of treatment (that included discussion of
their ratings of cognitive and physical performance).
Patient 1 was a woman in her early twenties who had suffered her first MS attack in the
previous year. The attack had led to paralysis down her left side and required hospital admission.
While she recovered almost all her physical functioning, she continued to notice numbness
and tingling in her left arm and leg. At assessment she reported spending a great deal of time
worrying about the future. In particular, she had images of herself back in hospital following a
relapse and permanently disabled. Her concern was that if this happened, other people would
have to look after her and she would be a burden to them. The thought that frightened her the
most was that she would be unable to care for her young child. She spent long periods of time
rubbing her arm to ensure she could still feel sensation in it. Whenever she noticed tingling or
numbness in her arms or legs she would stand up and move around. Her belief was that if she
could still move them, she was not experiencing a relapse. She would repeat this behaviour
frequently during the day.
At first, Patient 1 engaged well in therapy but found talking about her fears for the future
distressing, ending most of the sessions in tears. Through collaborative formulation, she
recogniszd that while her images about the future may be accurate (physically disabled),
the meanings she attributed to them may not be (being a bad mother/burden to others). She
also recognized that her checking behaviour (rubbing her arm to ensure she still had sensation)
was keeping her preoccupied with thoughts about her MS and thus maintaining her anxiety.
After guided discovery around the value of rubbing her arm during the second session, she
spontaneously dropped this behaviour before the third session. In Fig. 1, Patient 1’s VSHAI
score can be seen to drop following her second session, suggesting a fall in her level of HA.
However, at the third session a behavioural experiment was developed to help her examine what
would happen if she dropped her other checking behaviour (standing and moving around to
ensure her legs still worked). Her belief was that if she did not do this she would miss the onset
of a next attack and while she stated she was happy to try the experiment, she did not attend
her next scheduled sessions. When she was finally seen some weeks later, it emerged she was
experiencing flashbacks to her time in hospital and being paralysed down her left side. She did
not attend any further sessions so it was not possible to assess whether she was experiencing a
trauma reaction that was inadvertently being triggered during treatment sessions that focused
on her MS. The implications of this for treatment are discussed below (see Discussion).
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Figure 1. Ratings of health anxiety (SHAI, Short Health Anxiety Inventory; VSHAI, Very Short Health
Anxiety Inventory) and mood (PHQ-9, Patient Health Questionnaire) during baseline, treatment and five
month follow-up.
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Patient 2 was a woman who had been diagnosed with RRMS 3 years prior to the present study.
Her main symptoms from her first recognized MS attack had been blurring of vision, fatigue
and pain in her lower back. She has a general distrust of medical professionals; previously,
when her eldest child was young and suffering a life-threatening illness, she believed it was
only through her battling to secure treatment that saved their life. At her initial assessment, she
reported spending long periods worrying about the future. These worries were about becoming
physically disabled and unable to look after her children. She remained vigilant for physical
signs she was relapsing and would use the internet to check the implications of her symptoms.
She would also use the internet to keep abreast of the latest research in MS and ensure that she
was prepared for her next relapse in terms of being able to ask the medical professionals for
the most effective treatment.
Through discussion, Patient 2 recognized that she was less anxious about her future when
she was looking after her children and too busy to use the internet (i.e. Theory B). While
she did not engage in any overt checking of any physical signs of relapse, she did admit to
remaining vigilant for them. A behavioural experiment was also developed to assess the impact
of checking the internet on her HA. As she was reluctant to reduce this safety behaviour, she
agreed to increase her checking on alternate days and compare ratings of anxiety against the
days she checked at her usual level. In doing so she recognized that her checking behaviour was
increasing her preoccupation with her health and subsequently reduced the number of times
she checked the internet to once daily. Her treatment sessions also focused on differentiating
the process of worry from its content and recognizing it was the repetitive negative thought
processes and safety behaviours (checking the internet), that were maintaining her distress.
Given her wish to utilize mindfulness techniques, these were introduced in her third session
(a standard breathing meditation) to help her recognize her thoughts when they arrived in her
mind, but not to engage in the process of worry with them. In Fig. 1, a change in trend in Patient
2’s VSHAI score can be seen following this third session. While she struggled with meditation,
she was very engaged with the concept and stated she wanted to continue practising following
the end of treatment.
Patient 3 was a woman diagnosed with RRMS 2 years prior to the entering the present study.
She was anxious about her future and experienced intrusive images of herself in a wheelchair
unable to do anything for herself. Her main concern was that she would become a burden to
others who would eventually resent her. While she had discussed her condition with her partner
and he had reassured her he would not abandon her, she nevertheless remained concerned that,
faced with the reality of the condition, this might happen. Most mornings when she awoke
she would open her eyes and scan her bedroom to ensure that her vision was still working.
During a recent appointment with a neurologist he had asked her to touch each of her fingers
with her thumb. She now did this a number of times a day to check that her arms were still
functioning.
Guided discovery helped Patient 3 to realize that not all her physical sensations were signs of
relapse. Psycho-education on the role of adrenaline and ‘fight or flight’ response helped her to
have more helpful responses to signs of anxiety, rather than worry her disease was progressing.
At her second treatment session, the value of knowing when a relapse had occurred was
discussed and hence she devised with the therapist a behavioural experiment around reducing
her thumb tapping. While this experiment was to resist thumb tapping on alternate days and
compare her anxiety on these days with the days when she did thumb tap, she did not engage in
the behaviour at all over the subsequent week and at the fourth session she reported dropping
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the behaviour completely. In Fig. 1, a change in trend in VSHAI scores can be seen following
her second session after discussing her perception of physical and cognitive ability with her
actual scores at assessment and development of her behavioural experiment around thumb
tapping.
Patient 4 was a woman who had received her initial diagnosis almost 10 years earlier. She
experienced intrusive images of herself in the future being unable to care for herself. Her
worry was that in the future, her child would have to look after her and resent her for this.
Rather than inflict this on the child, she believed the child would have to be cared for by others
in the family and thus ‘lose’ her child. These intrusive images and thoughts occurred often
during the day but were mainly associated with times when she was alone and had time to
think.
Treatment initially involved exploring her perception of her physical and cognitive abilities
(see ‘Procedure’ section) before exploring by way of psychoeducation, how images can
be manipulated and changed to become less distressing (no actual imagery rescripting was
necessary for this patient). Treatment then focused on recognizing how the repetitive process
of worry kept her mind preoccupied on MS and was not necessarily accurate (i.e. Theory B). A
pie chart technique was used to help her see that she could continue to be a good mother even
when physically disabled. The concept of ‘worry time’ was presented in her third treatment
session to help her gain control over her worrying. She reported that ‘worry time’ (setting aside
a specified period of the day to worry) had a profound effect on her beliefs about controlling
her worry and resulted in her worrying less about her MS. This is consistent with the fall in
her VSHAI score in Fig. 1 following her third treatment session.
Treatment outcomes
The outcome of treatment in Study 2 on measures of HA (SHAI, VSHAI) and mood
(PHQ-9) are presented in Fig. 1. At the start of treatment all participants had SHAI scores
above threshold (18) for a diagnosis of hypochondriasis. Treatment was tracked each session
using the VSHAI and PHQ-9. Visual inspection of the data for each patient in Fig. 1 reveals
that Patients 2, 3 and 4 showed a level change reduction in SHAI score (p < .05) between
baseline and the end of treatment. For Patient 2, this brought her to below the threshold for
a diagnosis of hypochondriasis (18) while for Patients 3 and 4 their score fell to below 10
with an RC of 4.26 and 4.74, respectively, suggesting large effects of treatment and suggesting
they no longer suffered from HA. Inspection of the VSHAI scores in Fig. 1 suggest that the
change in trend for these patients happened after the second (Patient 3) or third (Patients 2
and 4) treatment session. Patient 1’s SHAI score had increased by the end of treatment but the
change was not statistically significant. The change in trend downwards of her VSHAI score
also happened after the second session for Patient 1; however, this was reversed by the time
she attended her fourth treatment session.
There was also a change in trend and level for PHQ-9 scores across all patients. Patients 1,
3 and 4 showed a significant reduction in PHQ-9 scores by the end of therapy (p < .05) while
Patient 2’s PHQ-9 score was already low at baseline. For Patients 1, 3 and 4 the change in
trend occurred following the first treatment session while for Patient 2 it was after her second
session. Subjective quality of life ratings for the patients are presented in Table 4 with all of
the patients showing improvements in QLI between baseline and end of treatment.
At 5-month follow-up all patients, with the exception of Patient 1 who dropped out of
therapy, had maintained the gains achieved during treatment.
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Table 4. Quality of Life Index (QLI) scores for patients at baseline, end of treatment and 5-month
follow-up
Baseline Post-treatment 5-month follow-up
Patient 1 11.16 12.47 n/a
Patient 2 15.59 17.00 19.00
Patient 3 14.41 23.24 23.70
Patient 4 18.99 22.30 26.30
Discussion
In Study 1, consistent with Hayter et al. (2016) it was found that MS patients with high HA
rated their QoL lower than those with lower levels of HA, a difference that remained significant
even when physical disability was accounted for. Study 2 extends this work by reporting
preliminary findings on the impact of CBT-HA for HA in MS. A brief course of CBT-HA
led to improvements not only in HA but also in quality of life and mood, improvements that
retained at 5-month follow-up. To our knowledge, this is the first study examining the treatment
of such anxiety in MS and represents a significant first step in developing effective treatments
for this population. Note that in the current study the difference between the groups in HA was
not as large as in the Hayter et al (2016) study.
Given the high rates of HA found in the MS population of between 25 and 30% (Hayter et al.,
2016; Kehler and Hadjistavropoulos, 2009) and the concomitant cost of HA to health services
(Tyrer et al., 2011a) the results reported here would suggest that HA should be more widely
screened for and treated in MS patients. Results overall are consistent with cognitive accounts
of anxiety and depression whereby symptoms are maintained through biased appraisals.
Hayter et al. (2016) allocated participants to groups using different criteria to the one
employed here: the health anxious group had to score above 18 on the SHAI and for the
non-health anxious group, 10 or lower. In the present study a median-split was used to allocate
to groups and thus there was not as clear a dichotomy between them. This may explain why
Hayter et al. found a significant difference between groups on a measure of mood whereas
Study 1 did not. However, in Study 1 the mean score on a measure of depression (PHQ-9) was
above cut-off in the HiHA group and below cut-off in the LowHA, suggesting a correlation
between HA and mood, but the difference between groups was not statistically significant.
This may have been due to the lower number of participants in the Study 1 which is a general
limitation of the study as a whole. The link between HA and mood is given further weight
with the finding in Study 2 that when HA is treated, mood improved also. A further limitation
of Study 1 is that it did not include a control group. However, given the similarities in the
main findings across studies, we feel confident that the effects found in Study 1 and Hayter
et al. are consistent with cognitive accounts of anxiety and depression whereby symptoms are
maintained through biased appraisals.
A limitation of Study 2 was that only two data points were available at baseline and thus
we were unable to establish stability of the measures at this stage. This might suggest that
the change in scores between baseline and the end of therapy are not as large as we suggest.
To counter this we would argue that the changes in SHAI for three of the participants were
large, even with a declining trend, and also correlate with improvements in mood and quality
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of life as well, in line with a cognitive account of HA in RRMS. A further limitation of Study
2 was a lack of control for non-specific effects of attending therapy. The initial plan was to
include further baseline measurement and to counterbalance the six sessions of CBT with
six relaxation training sessions but time limitations meant this was not possible. Given the
theoretical rationale for the success of CBT-HA, it is not expected that the general findings
would change with the inclusion of a control. Improvements to the design of Study 2 would
be the inclusion of extended baseline with the potential inclusion of continuous idiographic
measure of behaviours such as checking or reassurance seeking to support the standardized
measures of HA and mood. This would provide greater assurance that the difference between
baseline and the end of treatment was a result of the CBT-HA intervention.
Clinical implications
The case series suggests that treating HA in MS is possible using an adapted CBT approach
(CBT-HA) that leads not only to improvements in HA, but also in mood and subjective quality
of life. The replication of Hayter et al. was driven in part to identify targets for treatment
during CBT-HA sessions. These were in the form of behavioural experiments that included
explorations of the meanings of physical and cognitive symptoms through discussion of the
participants’ objective and perceived scores on the cognitive and physical tasks. The use of
behavioural experiments in treating anxiety in not new (e.g. Salkovskis et al., 2003) but the
present study builds on previous work by suggesting that a focus on specific targets for treatment
(misappraisals of physical and cognitive functioning) can lead to significant symptom reduction
in MS patients.
A large part of the treatment also focused on participants’ worries about the future; in
particular what would happen if they became physically disabled. All the patients reported
intrusive images of them as physically disabled in the future and unable to care for themselves.
These are consistent with findings from Wells and Hackmann (1993) that images of a feared
future in HA are often associated with fear of abandonment and an underestimation of coping
abilities. Physical disability is a potential reality for many MS sufferers and for this reason may
not represent a viable target for therapist treating HA. However, the treatment here focused on
the meanings the participants attributed to this dreaded future. Across all four participants it
was a concern they would become a burden to their families. Exploration of these meanings
through use of Socratic questioning and guided discovery helped them to alter the meaning of
the images such that while physical disability was a distinct possibility, becoming a burden (or
being a bad mother) was not. Furthermore, the direct manipulation of an intrusive image by one
patient led to reductions in the negative emotions associated with it (for review, see Holmes
and Mathews, 2010). The present case series suggests that a potential target in therapy is the
unique meaning patients attribute to intrusive images in order to help them develop strategies
to reduce psychological distress.
For Patient 1 in Study 2, after her third treatment session she reported other images that
appeared consistent with experiencing a flashback to her stay in hospital and suggestive of a
trauma reaction to this. The reason this did not emerge until later in treatment is likely to be
due to her avoidance of triggers of re-experiencing and arousal symptoms. When she felt more
trusting of the therapist this avoidance may have decreased but the triggering of symptoms is
likely to have led to her disengagement with treatment. Post-traumatic stress disorder (PTSD)
can present with elements of any of the other anxiety disorders (Butler et al., 2008) with
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around 60% of patients with PTSD meeting criteria for at least one other disorder (Kessler
et al., 1995). However, care is needed here as an emerging view in the recent literature is that
intrusive images of past trauma or feared events are not confined to PTSD. Handley et al.
(2009) found that the majority of patients screened for travel phobia following the London
bombings in 2005 also had PTSD symptoms; with some of them reporting intrusive trauma
memories and hyper-arousal. They suggest that while patients may not have met full criteria for
a PTSD diagnosis, treatment should incorporate elements of PTSD treatment to help patients
overcome their re-experiencing symptoms (e.g. Ehlers and Clark, 2000). This seems especially
relevant to patients with RRMS as their initial attack or relapse can happen suddenly with
devastating impact on physical functioning (as happened with Patient 1) and experienced as a
life-threatening trauma. The experience of treating Patient 1 suggests that clinicians need to be
vigilant of PTSD symptoms in RRMS patients presenting with psychological complications
(even if they do not meet full criteria for a PTSD diagnosis) so they can get the most appropriate
treatment. Unfortunately for Patient 1, her reluctance to return to treatment meant this was not
possible.
Future research
The similarity of the intrusive images (and to a large part the meanings attributed to them) across
all of the patients in the present case series is intriguing. Previous research by Berna et al. (2011)
in patients with chronic pain revealed a wide variation in the content and meaning of intrusive
of images. The similarities of images found here may have been due to the patients’ similar
personal circumstances (all mothers with children living at home). It remains an empirical
question as to whether the similarity of intrusive images found here is reported across the MS
patient population more generally. If so, future research might consider whether the similarities
are accounted for by an aspect of MS or its interaction with cognitive processes involved in
the development and maintenance of HA (or anxiety disorders more generally). The extent to
which these images are malleable through therapy is also a question for further research. Here
the meanings of the negative images were successfully targeted but other approaches (such as
imagery rescripting or retraining; Holmes et al., 2007) may lead to even greater therapeutic
gains.
In Study 1, QoL was reduced for MS patients with HA compared with the non-HA patients,
and improved following treatment (Study 2). These findings suggest that HA has a direct
negative impact on QoL, but it remains unclear which specific mechanisms are involved.
Future research might consider whether it is behavioural (e.g. safety seeking behaviours) or
cognitive (e.g. negative intrusive thoughts/images) that are most responsible for reduced QoL
and help to prioritize targets for treatment. Other research has targeted ‘fear of progression’
in chronic or progressive diseases. For example, Herschbach et al. (2010) found a that four-
session group CBT approach for cancer patients reduced fear of progression as well as levels
of anxiety and depression. It would be interesting to include a measure of ‘fear of progression’
in future work in MS.
Conclusions
The findings from this research support the findings from Hayter et al. (2016) where in MS
patients HA reduces quality of life, over and above their level of physical or cognitive disability.
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Furthermore, they see their cognitive and physical functioning as more impaired than it actually
is. Given the high prevalence rate of HA in this population, and the economic burden to
health care services of patients suffering HA, Study 2 suggests that a brief CBT intervention
that targets misappraisals of cognitive and physical performance as well as intrusive imagery
about their feared future, could significantly improve MS patients’ wellbeing. Replicating
the findings of Study 2 with improvements to the single case design (e.g. extended baselines)
would pave the way for larger, controlled studies to demonstrate the effectiveness of this type of
intervention.
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Appendix: Calculation of Reliable Change Index (from Jacobson and Truax, 1991)
Let X1 = pre-test score; X2 = post-test score; rxx = test–retest reliability of measure; Sdiff = standard
error of difference between the two test scores; SE = standard error of measurement.
Reliable change index (RC) is calculated by the following equation:
RC = X2 − X1
Sdiff
where Sdiff = √2(SE )2 and SE = Sx√ (1 − rxx ) .
An RC larger than 1.96 would be unlikely to occur (p < .05) without actual change. When RC exceeds
this level, the individual can be classified as reliably changed.
The Health Anxiety Inventory has a test–retest reliability of 0.76. The standard deviation of SHAI
scores in the HiHA group was 3.04. Using the above formulae, SE = 1.49 and Sdiff = 2.11.
For Patient 2 RC = (25 − 16) /2.11 = 4.26
Patient 3 RC = (18 − 9) /2.11 = 4.26
Patient 4 RC = (18 − 8) /2.11 = 4.74
All values are above the cut-off of 1.96 and represent large and significant change (p < .05).
